Figure 3.

Actuarial disease-free survival of Interleukin-2 group and control group according to Phase 2 randomization to IDADCTER (idarubicin, cytarabine, thioguanine, etoposide, and daunorubicin) and FLU IDA (fludarabine monophosphate, cytarabine and idarubicin)